I am still sticking with my $16 share price prediction by Feb/March 2023....
Think we will get close to $10 on ROW deal, content of the deal will dictate more value....
FDA decision (95% success) will push us to the $14-$16 range I think easily....
Neu cash flow 2022-2023 is minimum $118m. not including cash from ROW upfront and royalties in any sales on Trof..
This valuation is on Trof asset alone, looming results for Phase 2 trials will potentially support/boost share price...
Hopefully no TO until we get phase 2 trial results in my view also, I feel Jon and team want to see this also...
Think this time next year $20 is also possible (12 month time)
I am still sticking with my $16 share price prediction by...
-
- There are more pages in this discussion • 9,280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.09 |
Change
0.000(0.00%) |
Mkt cap ! $2.184B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 555 | $17.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.00 | 1600 | 1 |
View Market Depth
| Last trade - 12.24pm 07/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable